CHRS — Coherus Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1512762 ·
Last close
$1.14
Market Cap
$176.13M
52W High
$2.62
52W Low
$1.09
ADV30
1,358,044
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,307,000 | 10,065,000 | -32,331,000 | -20,631,000 | 191,183,000 | 82,923,000 | 130,345,000 |
| Mar 2026 | 12,310,000 | 8,496,000 | -36,151,000 | -38,327,000 | 266,022,000 | 115,238,000 | 187,399,000 |
| Dec 2025 | 12,748,000 | 8,703,000 | -45,880,000 | -37,643,000 | 258,343,000 | 88,879,000 | 197,329,000 |
| Sep 2025 | 11,571,000 | 7,850,000 | -44,333,000 | -35,531,000 | 516,519,000 | 103,352,000 | 428,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,031,000
Investing CF
$-9,779,000
Financing CF
$61,817,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.03
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,441,927,000
Inventory
$5,667,000
Receivables
$14,253,000
ST Investments
$22,383,000
EBIT TTM
$-152,063,000
Pretax Income TTM
$-161,146,000
Interest Exp TTM
$9,083,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$50,936,000
EBITDA
$-150,390,000
Free Cash Flow
$-160,150,752
Enterprise Value
$154,357,280
Total Cash
$105,306,000
Total Debt
$54,177,000
Shares Out
154,500,966
Trailing EPS
$-1.24
Book Value
$0.39
ROE
-178.4%
ROA
-30.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,172,000 | -181,134,000 | 168,024,000 | 258,343,000 | 197,329,000 | 61,014,000 | -138,513,000 |
| Dec 2024 | 26,389,000 | -199,653,000 | 28,507,000 | 448,533,000 | 580,523,000 | -131,990,000 | -20,440,000 |
| Dec 2023 | 257,244,000 | -203,199,000 | -237,892,000 | 629,604,000 | 823,029,000 | -193,425,000 | -174,884,000 |
| Dec 2022 | 211,042,000 | -256,880,000 | -291,754,000 | 480,847,000 | 618,265,000 | -137,418,000 | -241,124,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.63
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.14 · call volume: 152 · put volume: 193
Expected Move to 2026-11-20:
±$0.40
(35.09%) —
implied range
$0.74 –
$1.54
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | $172.23M | $6.24 | — |
| IPHYF | Innate Pharma SA | $184.31M | $1.65 | — |
| VYGR | Voyager Therapeutics, Inc. | $166.37M | $2.70 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $166.33M | $2.30 | — |
| ACOG | Alpha Cognition Inc. | $187.29M | $8.60 | — |
News headlines (Yahoo Finance, 1h cache)
Coherus to Participate in Upcoming Investor Conferences
2026-08-31 13:30 · Yahoo
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
2026-08-13 00:31 · Yahoo
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...
2026-08-06 05:03 · Yahoo
Coherus Oncology Q2 Earnings Call Highlights
2026-08-06 00:04 · Yahoo
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
2026-08-05 22:10 · Yahoo
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 17:36 · Yahoo
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
2026-06-23 18:00 · Yahoo
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today
2026-05-14 12:16 · Yahoo
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
2026-06-11 11:39 · Yahoo
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary
2026-05-12 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.